Title: Cytotoxicity of 34 FDA approved small-molecule kinase inhibitors in primary rat and human hepatocytes.
Journal: Toxicology letters20180701
Title: Absorption, Metabolism, Excretion, and the Contribution of Intestinal Metabolism to the Oral Disposition of [14C]Cobimetinib, a MEK Inhibitor, in Humans.
Journal: Drug metabolism and disposition: the biological fate of chemicals20160101
Title: MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy.
Journal: Drug design, development and therapy20160101
Title: Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors.
Journal: Cancer chemotherapy and pharmacology20151101
Title: Cobimetinib: First Global Approval.
Journal: Drugs20151001
Title: Targeted inhibition of MEK1 by cobimetinib leads to differentiation and apoptosis in neuroblastoma cells.
Journal: Journal of experimental & clinical cancer research : CR20150101
Title: Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.
Journal: Nature20130912
Title: MEK and the inhibitors: from bench to bedside.
Journal: Journal of hematology & oncology20130101
Title: Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition.
Journal: Cancer research20120101
Title: The role of BRAF V600 mutation in melanoma.
Journal: Journal of translational medicine20120101
Title: Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.
Journal: Cell20040319
Title: Mutations of the BRAF gene in human cancer.
Journal: Nature20020627
Title: Hoeflich KP, et al. Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition. Cancer Res. 2012 Jan 1;72(1):210-9.
Title: Choo EF, et al. PK-PD modeling of combination efficacy effect from administration of the MEK inhibitor GDC-0973 and PI3K inhibitor GDC-0941 in A2058 xenografts. Cancer Chemother Pharmacol. 2013 Jan;71(1):133-43.
Title: Wong H, et al. Bridging the gap between preclinical and clinical studies using pharmacokinetic-pharmacodynamic modeling: an analysis of GDC-0973, a MEK inhibitor. Clin Cancer Res. 2012 Jun 1;18(11):3090-9.
Title: Corazao-Rozas P, et al. Mitochondrial oxidative phosphorylation controls cancer cell's life and death decisions upon exposure to MAPK inhibitors. Oncotarget. 2016 Feb 29. doi: 10.18632/oncotarget.7790.
